VEXAS syndrome has an unmet need for therapeutic interventions. Even if few data exist
regarding the treatment of this newly described syndrome, different options can be proposed …

Graft failure is a serious complication of allogeneic hematopoietic stem cell transplantation
(allo-HSCT) defined as either lack of initial engraftment of donor cells (primary graft failure) …

Posttransplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis has
enabled haploidentical (Haplo) transplantation to be performed with results similar to those …

Purpose T-cell–replete HLA-haploidentical donor hematopoietic transplantation using post-
transplant cyclophosphamide was originally described using bone marrow (BM). With …

Background Donors other than matched siblings and low-intensity conditioning regimens
are increasingly used in haematopoietic stem cell transplantation. We aimed to compare the …

Mesenchymal stem cell (MSC) therapies demonstrate particular promise in ameliorating
diseases of immune dysregulation but are hampered by short in vivo cell persistence and …

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

Clinical outcomes after primary graft failure (PGF) remain poor. Here we present a large
retrospective analysis (n= 23 272) which investigates means to prevent PGF and early …

Poor graft function (PGF), defined by the presence of multilineage cytopenias in the
presence of 100% donor chimerism, is a serious complication of allogeneic stem cell …

Severe acute graft-versus-host disease (GVHD) is a life-threatening complication after
allogeneic hematopoietic stem cell transplantation (HSCT). The placenta protects the fetus …